Jefferies keeps a USD 36.00 target for Pfizer stock

Published on 10/27/2026 at 17:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue guidance rose to USD 60.5-62.5 billion on August 4, 2026. Pfizer stock costs EUR 26.68 on October 27, 2026, unchanged versus the Xetra close.

Analyst target and reporting date

Jefferies maintained a USD 36.00 target and Buy rating for Pfizer on October 26, 2026.
Revenue guidance rose to USD 60.5 billion to USD 62.5 billion for 2026 on August 4, 2026.
Pfizer stock costs EUR 26.68 at Lang & Schwarz on October 27, 2026 at 5:33 p.m. CET, unchanged versus the Xetra close of October 27, 2026.
Pfizer's next earnings release is scheduled for November 3, 2026, followed by a November 6, 2026 ex-dividend date.

Pfizer Inc., US7170811035, Illustration mit AI erstellt.

Pfizer Inc. (ISIN US7170811035) has a USD 36.00 target and Buy rating from Jefferies, which maintained both on October 26, 2026, according to MarketScreener. The target stood 21.09 percent above Pfizer's USD 29.73 Nasdaq price at 12:34 p.m. EDT on October 27, 2026. Pfizer was trading at EUR 26.68 at Lang & Schwarz on October 27, 2026 at 5:33 p.m. CET, unchanged versus the Xetra close of October 27, 2026.

Guidance moved higher

Pfizer's second-quarter 2026 revenue reached USD 15.03 billion, representing 1.00 percent operational growth from the prior year. Adjusted diluted earnings per share came to USD 0.77, while reported diluted earnings per share were minus USD 0.04, according to the Yahoo Finance transcript dated August 4, 2026. Pfizer raised full-year 2026 revenue guidance to USD 60.5 billion to USD 62.5 billion from USD 59.5 billion to USD 60.5 billion, a USD 1.50 billion increase at the midpoint.

Price position and valuation

The Lang & Schwarz price was EUR 26.68 after the Xetra close, matching the Xetra close of October 27, 2026. Pfizer's primary-market quote was USD 29.73 on the New York Stock Exchange at 12:34 p.m. EDT on October 27, 2026. The USD 23.62 to USD 30.44 52-week range puts that quote 2.33 percent below the high. Pfizer's market capitalization was USD 169.4 billion and its price-to-earnings ratio was 39.26 on October 27, 2026.

Dates and peer comparison

MarketScreener lists November 3, 2026 as Pfizer's next earnings release. Yahoo Finance also lists November 6, 2026 as the ex-dividend date for the USD 0.43 quarterly dividend. Those dates place the next operating update and the next dividend milestone within the same week.

Comparison with peers

Pfizer Inc.: unchanged, P/E 39.26, market capitalization USD 169.4 billion
Merck & Co.: up 1.19 percent, P/E 113.73, market capitalization USD 351.0 billion (NYSE, USD)
Bristol-Myers Squibb: down 0.30 percent, P/E 13.52, market capitalization USD 125.5 billion (NYSE, USD)

What the target implies

Jefferies' USD 36.00 target is materially above Pfizer's USD 29.73 New York Stock Exchange quote, while the latest quarterly figures combine 1.00 percent operational revenue growth with a USD 0.77 adjusted diluted earnings-per-share result. The November earnings date will provide the next scheduled test of the raised revenue outlook.

Pfizer was trading at EUR 26.68 at Lang & Schwarz on October 27, 2026 at 5:33 p.m. CET, unchanged versus the Xetra close of October 27, 2026. The further course of trading is shown by the continuously updated real-time quote of Pfizer stock.